Study to Determine the Pharmacokinetics of Product 0405

Fougera Pharmaceuticals

Status and phase: Withdrawn; Phase 3

Conditions: Atopic Dermatitis

Treatments: Drug: Product 0405

Study type: Interventional

Funder types: Industry

Identifiers

NCT02176577

0405-01-07

Details and patient eligibility

About

The purpose of this study is to evaluate the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects.

Full description

Treament medication will be administered topically twice daily for 28 days.

Sex: All

Ages: 3 months to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of Atopic Dermatitis
• Good health with the exception of Atopic Dermatitis
• Percent body surface area minimums

Exclusion criteria

• Subject who are nursing, pregnant or planning a pregnancy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Product 0405

Experimental group

Description:

Topically Active Investigational Product 0405

Treatment:

Drug: Product 0405